Leading experts in immuno-oncology will provide an overview of the current landscape in immuno-oncology and the need for new T-cell stimulatory agents, such as NKTR-214 and NKTR-255. For the first time,
Pain management specialists will discuss opioid-induced constipation and new first-in-class medicine MOVANTIK™, as well as review the regulatory landscape for abuse-deterrent analgesics. New in vitro manipulation and extraction data will be presented for NKTR-181, a first-in-class, mu-opioid analgesic investigational drug candidate with a novel molecular structure designed to reduce abuse liability.
The experts will also participate in two separate panel discussions on current treatment practices and share their perspectives on the medical need for new treatment options.
"Today's presentations will highlight the significant promise of our internally discovered programs, particularly in immuno-oncology, which have the potential to drive the next stage of growth for
Webcast Information
The live webcast from will start at
About
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark of the AstraZeneca group of companies.
ADYNOVATE is a trademark of Baxalta Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the value and potential of our polymer conjugate technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (ii) patents may not issue from our patent
applications for our drugs and drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (iii) the outcome of any existing or future intellectual property or other litigation related to our drugs and drug candidates and those of our collaboration partners. Other important risks and uncertainties set forth in our Annual Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2015. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Media
Nadia Hasan of WCG
212-257-6738
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-reports-on-advancements-with-pain-and-oncology-clinical-pipeline-at-investor-and-analyst-rd-day-300156696.html
SOURCE
News Provided by Acquire Media